Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,508 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Postoperative Pain
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Labor, Induced, Oxytocin
Interventions: Oxytocin; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate; Drug · Other · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Kidney Diseases, Hyponatremia
Interventions: conivaptan hydrochloride; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Prostate Cancer
Interventions: PBRT, PLNRT, AA, LHRH agonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 444
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more

Conditions: Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
Interventions: Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sarcoma
Interventions: graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: ESRD
Interventions: anakinra, actos, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions: Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes; Drug · Radiation · Procedure + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 39
States / cities: Duarte, California • San Francisco, California • Stanford, California + 28 more

Conditions: Prostate Cancer
Interventions: Abiraterone, Leuprolide, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more

Conditions: Acute Heart Failure
Interventions: Placebo, Nesiritide, Dopamine; Other · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more

Conditions: Alzheimer's Disease
Interventions: 11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional); Drug · Procedure
Lead sponsor: Patrick Lao; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-arginine, L-arginine Loading Dose, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 21 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Includes: Hereditary Angioedema
Interventions: Berinert® (C1 Esterase Inhibitor); Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 34
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more

Conditions: Blood Pressure, Cardiovascular Risk Factor
Interventions: Normal Protein, HIgh Protein; Other
Lead sponsor: Purdue University; Other
Eligibility: 21 Years to 121 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: COPD
Interventions: OnabotulinumtoxinA, Placebo; Drug · Other
Lead sponsor: RMW Testing; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions: Stem Cell Transplantation, Busulfan, Melphalan; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia
Interventions: filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: University of Nebraska; Other
Eligibility: 1 Year to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2005
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Kidney Cancer
Interventions: Interleukin-2; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Oakland, California + 11 more

Conditions: Healthy
Interventions: Vasopressin, Arginine, ADH, Placebo; Sterile Saline; Drug
Lead sponsor: Bowdoin College; Other
Eligibility: 18 Years to 30 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Search by objective public record fields.

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Oxytocin Dosage to Decrease Induction Duration

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

Imaging Inflammation in Alzheimer's Disease

Arginine Therapy for Sickle Cell Disease Pain

Patient Registry Study of Berinert® in Normal Clinical Practice

The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Vasopressin Effects on Human Social Communication

STOP-T1D Low-Dose (ATG)